Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2024Clinical Chemistry and Laboratory Medicine (CCLM)

An ultrasensitive DNA-enhanced amplification method for detecting cfDNA drug-resistant mutations in non-small cell lung cancer with selective FEN-assisted degradation of dominant somatic fragments

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJunhua ZhangYLYifei LiWHWei Huang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e5e4ecb6db6435875799bahttps://doi.org/10.1515/cclm-2024-0614
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CRISPR with a Double Mismatch Guide RNA Enhances Detection Sensitivity for Low-Frequency Single-Base EGFR Mutation in Circulating Cell-Free DNA of Lung Cancer Patients2025 · 4 citations
  2. 2Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCLC2024 · 2 citations
  3. 3A “turn-on” CRISPR-mediated method using enhanced fluorescent bimetallic DNA nanoclusters for EGFR mutation detection in non-small cell lung cancer2026
  4. 4Electrochemical-Fluorescent Bimodal Biosensor Based on Dual CRISPR-Cas12a Multiple Cascade Amplification for ctDNA Detection2024 · 16 citations
  5. 5CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma2024 · 23 citations